A CD33-deleted allograft (trem-cel) enables post-hematopoietic cell transplant (HCT) maintenance dosing of gemtuzumab ozogamicin (GO) with therapeutic levels of drug exposure and low hematologic and hepatic toxicity in patients with high-risk acute myeloid leukemia (AML) Meeting Abstract
| Authors: | DiPersio, J. F.; Koehne, G.; Shah, N. N.; Bernard, L.; Suh, H. C.; Koura, D.; Perales, M. A.; Tamari, R.; Mushtaq, M. U.; Maakaron, J. E.; Loken, M. R.; Stanizzi, D.; Lee-Sundlov, M. M.; Thosar, S.; Hyzy, S.; Raffel, G. D.; Cooper, B. W. |
| Abstract Title: | A CD33-deleted allograft (trem-cel) enables post-hematopoietic cell transplant (HCT) maintenance dosing of gemtuzumab ozogamicin (GO) with therapeutic levels of drug exposure and low hematologic and hepatic toxicity in patients with high-risk acute myeloid leukemia (AML) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 2873 |
| Language: | English |
| ACCESSION: | WOS:001415696500012 |
| DOI: | 10.1182/blood-2024-205641 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
